As­traZeneca, Sanofi's RSV an­ti­body set for FDA ad­comm on Thurs­day

The FDA’s An­timi­cro­bial Drugs Ad­vi­so­ry Com­mit­tee is set to meet Thurs­day to dis­cuss As­traZeneca and Sanofi’s RSV an­ti­body nir­se­vimab, mak­ing it the third ther­a­py aimed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER